趋化因子受体CXCR4在乳腺癌组织中的表达及其意义
Expr ession and Clinical Significance of the CXC Chemokine Receptor - 4 (CXCR4) in Br east Cancer
-
摘要: 目的:探讨趋化因子受体CXCR4在乳腺癌中的表达及其与临床病理学参数的关系。方法:采用半定量RT-PCR和免疫组织化学法分别检测121例乳腺癌新鲜组织及对应75例石蜡组织中CXCR4 mRNA及蛋白的表达。结果:乳腺癌中CXCR4m RNA及蛋白的表达阳性率分别为30.58%、68%;CXCR4 mRNA表达与蛋白表达呈显著正相关(χ2=5.049,P<0.05),且均与淋巴结转移关系密切,淋巴结转移阳性组CXCR4表达明显高于阴性组,差异具有统计学意义(P<0.05)。结论:CXCR4表达可能在促进乳腺癌淋巴结转移过程中起重要作用,其表达可作为判断乳腺癌恶性生物学行为并预测转移风险的一个指标,抑制CXCR4表达及其活性可为临床阻断癌细胞转移提供新的抗趋化治疗途径。Abstract: To investigate the expression of CXCR4 in breast cancer and its clinical significance. Methods: CXCR4 mRNA was detected in 121 fresh tumor tissues of breast cancer using semi- quantitative reverse transcription polymerase chain reaction (RT- PCR), and CXCR4 protein was examined in 75 corresponding formalin- fixed paraffin- embedded tissues by immunohistochemistry. Results: The positive rate of detection of CXCR4 mRNA and protein in mammary cancer was 30.58% and 68%, respectively. Furthermore, a high level of CXCR4 mRNA or protein was significantly associated with axillary lymph node metastasis (P<0.05). Conclusions: Our results suggest that CXCR4 expression is correlated with lymph node metastasis, and a high level of CXCR4 may play an important role in tumorigenesis and progression of breast cancer. Therefore, inhibition of the expression and activity of CXCR4 may provide a new target for anti- chemotaxis therapy in clinical settings.
下载: